Azenta, Inc. (NASDAQ:AZTA) CFO Sells $28,529.84 in Stock

Azenta, Inc. (NASDAQ:AZTA) CFO Herman Cueto sold 712 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $40.07, for a total transaction of $28,529.84. Following the completion of the transaction, the chief financial officer now owns 23,892 shares in the company, valued at approximately $957,352.44. This represents a 2.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Herman Cueto also recently made the following trade(s):

• On Thursday, October 17th, Herman Cueto sold 1,595 shares of Azenta stock. The stock was sold at an average price of $43.68, for a total value of $69,669.60.

Azenta Stock Performance

AZTA opened at $45.16 on Friday. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -15.21 and a beta of 1.48. The company has a fifty day moving average of $45.22 and a 200 day moving average of $50.12. Azenta, Inc. has a fifty-two week low of $38.82 and a fifty-two week high of $69.16.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.08. Azenta had a positive return on equity of 1.03% and a negative net margin of 25.01%. The business had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $169.66 million. During the same period in the prior year, the firm earned $0.13 EPS. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities research analysts forecast that Azenta, Inc. will post 0.4 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Needham & Company LLC decreased their target price on Azenta from $69.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Evercore ISI decreased their price objective on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $63.60.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in Azenta by 16.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,970,964 shares of the company’s stock worth $156,331,000 after purchasing an additional 421,719 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of Azenta by 16.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,298,856 shares of the company’s stock valued at $62,917,000 after buying an additional 183,040 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its holdings in shares of Azenta by 1.9% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 5,298,040 shares of the company’s stock worth $278,783,000 after buying an additional 100,826 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Azenta by 433.6% during the 2nd quarter. Squarepoint Ops LLC now owns 73,055 shares of the company’s stock worth $3,844,000 after acquiring an additional 59,364 shares during the last quarter. Finally, Royce & Associates LP boosted its holdings in Azenta by 7.8% during the 3rd quarter. Royce & Associates LP now owns 739,977 shares of the company’s stock valued at $35,844,000 after acquiring an additional 53,584 shares during the period. 99.08% of the stock is owned by hedge funds and other institutional investors.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.